An Immunotherapy Renaissance in Hepatobiliary Cancers

Immunotherapy has revolutionized the way we treat many malignancies, including hepatobiliary cancers. In this Grand Rounds, UCSF oncologists Katie Kelley, MD and Bridget Keenan, MD, PhD, will discuss the newest developments in using immunotherapy to treat these cancers as well as their unique bench-to-bedside translational approach.
Speakers
Katie Kelley, MD, is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests are in developing clinical trials of new treatments (including immunotherapy approaches) and combination therapies for these cancers, as well as translational research to identify molecular and genetic biomarkers of response.
Bridget Keenan, MD, PhD, is a physician-scientist who works in translational cancer research and medical oncology at the Cancer Immunotherapy Clinic. In the clinic, she cares for patients with solid organ cancers who are being treated on early phase immunotherapy trials. Her research focuses on the mechanisms of response and resistance to immunotherapy, particularly in gastrointestinal cancers.
Program
Bob Wachter: Introduction
2:40-10:30; 14:15-25:45; 39:00-41:25 - Katie Kelley, MD, gastrointestinal oncologist
10:30-14:15; 25:45-39:00- Bridget Keenan, MD, PhD, physician-scientist
48:00-1:00:50 - Q&A
See previous Medical Grand Rounds:
April 25: Diagnosis: Teaching, Measuring, Innovating
• Diagnosis: Teaching, M...
April 18: The Devastating Effect of Covid-19 on Patients with End-Stage Kidney Disease
• The Devastating Effect...
April 11: Immune Effector Cell Therapy in Hematologic Malignancies: Lessons Learned
• Immune Effector Cell T...
March 21: From Pipettes to Populations: Building an Integrated Program for ID Research and Education
• From Pipettes to Popul...